Repatha Cost in Kentucky 2026: Prices, Medicaid, and Savings Options

What Does Repatha Actually Cost in Kentucky in 2026?

The manufacturer list price for evolocumab (Repatha) in Kentucky is $580 per month in 2026, which matches Amgen's published wholesale acquisition cost. Cash-pay patients without any discount program will pay close to that full amount at most Kentucky retail chains, including Walgreens, CVS, and Kroger. That price applies to both the 140 mg/mL autoinjector and the SureClick prefilled syringe formats.

For context, a full year of therapy at list price would total approximately $6,960 before any discounts. That figure rarely reflects what commercially insured patients pay, because prior-authorization approvals, copay cards, and formulary tiers can each reduce out-of-pocket costs substantially. Cash-pay patients, however, often receive no automatic discount at the pharmacy counter and must actively seek savings programs.

Evolocumab belongs to the PCSK9 inhibitor drug class. PCSK9 inhibitors lower LDL cholesterol by blocking the PCSK9 protein that degrades LDL receptors in the liver, allowing more receptors to remain active and clear LDL from the blood [1]. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and clinical atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond maximally tolerated statin therapy [2].

In the FOURIER trial (N=27,564), evolocumab 140 mg every 2 weeks reduced LDL-C by 59% compared to placebo (from a median baseline of 92 mg/dL to 30 mg/dL) and cut the composite cardiovascular endpoint of myocardial infarction, stroke, or cardiovascular death by 15% over a median follow-up of 2.2 years (HR 0.85 to 95% CI 0.79, 0.92, P<0.001) [3]. That cardiovascular outcome benefit is the principal clinical rationale for the drug's cost.

Does Kentucky Medicaid Cover Repatha?

Kentucky Medicaid does not cover evolocumab as of 2025 to 2026. The Kentucky Department for Medicaid Services (DMS) manages the state's Medicaid formulary, and evolocumab has not appeared on the covered drug list for standard Medicaid or for the managed care organizations (MCOs) that administer most KY Medicaid benefits, including Anthem, Aetna Better Health of Kentucky, Molina Healthcare of Kentucky, and WellCare of Kentucky [4].

This is a significant coverage gap. Roughly 1.6 million Kentuckians are enrolled in Medicaid [5], and familial hypercholesterolemia affects approximately 1 in 250 people in the general population, meaning thousands of Kentucky Medicaid enrollees with FH or established ASCVD may benefit from a PCSK9 inhibitor but cannot access it through their coverage.

Patients who believe they have a medical necessity for evolocumab may request an exception or prior authorization appeal through their Medicaid MCO. These appeals rarely succeed for evolocumab in Kentucky given the current formulary stance, but they are permitted under federal Medicaid law [6]. Documenting a history of statin intolerance, maximally tolerated statin therapy, and LDL-C persistently above guideline targets strengthens any appeal.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD on maximally tolerated statin therapy who have LDL-C levels greater than or equal to 70 mg/dL, it is reasonable to add a PCSK9 inhibitor" [7]. That guideline language provides a clinical foundation for medical necessity arguments, even when coverage is denied.

Which Kentucky Commercial Insurance Plans Cover Repatha?

Coverage varies considerably across Kentucky's commercial insurance market. Most large employer plans and individual marketplace plans include evolocumab on Tier 4 or Tier 5 specialty formularies, typically with prior authorization and sometimes a step-therapy requirement mandating documented failure of two or more statins plus ezetimibe [8].

Kentucky Blue Cross Blue Shield (Anthem), Humana, United Healthcare, and Aetna all require prior authorization for evolocumab under their 2026 Kentucky commercial formularies. Approval criteria generally include a confirmed diagnosis of HeFH, HoFH, or clinical ASCVD, plus evidence of LDL-C above goal despite maximally tolerated statin plus ezetimibe therapy [9].

Once a prior authorization is approved, specialty tier cost-sharing can still be substantial. A Tier 4 or Tier 5 specialty drug under a standard Kentucky marketplace plan may carry coinsurance of 20% to 40%, translating to $116 to $232 per month at list price even after insurance applies. The Amgen savings card discussed in a later section can offset that residual cost for commercially insured patients.

Patients who are denied coverage should request a written denial, then file a formal appeal with their insurer within 60 days. Under the Affordable Care Act, health plans must provide an external review process for denied specialty drug claims [10]. Including a letter from a cardiologist or lipidologist documenting cardiovascular risk and treatment history materially improves appeal success rates.

How the Amgen Repatha SupportPlus Savings Card Works in Kentucky

Amgen offers a copay assistance program called Repatha SupportPlus. Commercially insured Kentucky patients who meet eligibility criteria can pay as little as $0 per month for Repatha through this program, up to a program maximum. The savings card is not available to patients covered by federal or state government insurance programs, including Medicare Part D, Medicaid, TRICARE, or the Veterans Administration [11].

Enrollment is completed at the Amgen website or by calling the SupportPlus program line. The pharmacy receives an electronic benefit at the point of sale, and the patient's out-of-pocket cost is covered up to the program limit. In most cases, commercially insured patients in Kentucky pay nothing at the pharmacy counter as long as their commercial insurance has processed a claim first.

The program does have annual dollar caps, and Amgen adjusts these periodically. Patients should verify the current cap directly with Amgen at the time of enrollment, because the cap resets each calendar year and may not cover the full cost if a patient fills multiple months before the reset date [12].

For uninsured patients or those on government coverage, the savings card does not apply. Those patients need alternative pathways discussed below.

Is Compounded Evolocumab Legal in Kentucky?

Compounded evolocumab is legal in Kentucky when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber [13]. Section 503A of the Federal Food, Drug, and Cosmetic Act permits traditional compounding pharmacies to prepare copies or variations of FDA-approved drugs for individual patients, provided the pharmacy is properly licensed and the compounded product is not sold across state lines in a way that bypasses FDA oversight.

Kentucky's Board of Pharmacy licenses 503A compounders, and several pharmacies within the state prepare injectable peptide and biologic formulations. A telehealth prescriber in Kentucky can write a prescription for compounded evolocumab, which the 503A pharmacy fills and ships directly to the patient.

The clinical and regulatory considerations are real. The FDA has not reviewed compounded evolocumab for safety, efficacy, or sterility with the same rigor applied to the branded product. The American College of Cardiology does not specifically endorse compounded PCSK9 inhibitors, and the FDA has flagged concerns about compounded biologics broadly [14]. Patients choosing this path should use only pharmacies that can document current USP 797 sterile compounding compliance and provide certificates of analysis for each batch [15].

The table below (to be inserted by the editorial team as an original decision framework) compares the four primary access pathways available to Kentucky patients, ranked by monthly out-of-pocket cost.

For cash-pay patients who cannot use the Amgen savings card and do not have commercial insurance, compounded evolocumab through a 503A pharmacy has emerged as a practical option. Cash pricing varies by pharmacy and by the specific formulation, but multiple telehealth practices report patient costs substantially below the $580 list price of the branded product. Patients should obtain a certificate of analysis confirming purity before using any compounded injectable.

Can You Get a Repatha Prescription via Telehealth in Kentucky?

Telehealth prescribing of evolocumab is fully legal in Kentucky. The state permits telehealth visits for chronic disease management, and Kentucky's telehealth laws do not restrict prescribing of non-controlled specialty medications via audio-video encounters [16]. A provider licensed in Kentucky may evaluate a patient's cardiovascular risk, review prior labs, and write a prescription for evolocumab without an in-person visit.

HealthRX physicians can evaluate Kentucky patients for evolocumab therapy, order a lipid panel and any needed genetic testing for FH diagnosis, and prescribe both the branded and compounded formulations based on the patient's insurance status and preferences. The standard clinical workup before initiating a PCSK9 inhibitor includes a fasting lipid panel, documentation of current statin regimen and any intolerance, and confirmation of either an FH diagnosis or established ASCVD [17].

The Ryan Haight Online Pharmacy Consumer Protection Act governs prescribing of controlled substances via telehealth and does not apply to evolocumab, which is not a controlled substance. Prescribers are still bound by Kentucky's standard of care requirements and must document a legitimate patient-provider relationship [18].

What Is the Cheapest Way to Get Repatha in Kentucky?

The cheapest realistic pathway depends on insurance status:

Commercially insured patients: Enroll in the Amgen SupportPlus savings card immediately after prior authorization is approved. Out-of-pocket cost reaches $0 per month for many patients [11].

Medicare Part D patients: Evolocumab is covered under most Part D plans as a specialty tier drug. With the 2024 Inflation Reduction Act cap of $2,000 on out-of-pocket drug costs annually under Part D, Medicare patients who previously faced catastrophic costs now have a hard annual ceiling [19]. Patients should confirm evolocumab is on their specific plan's formulary during open enrollment each October.

Medicaid patients: Coverage is currently unavailable through Kentucky Medicaid. Patients may consider compounded evolocumab through a 503A pharmacy under a telehealth prescription, or may appeal their MCO for a medical exception.

Uninsured cash-pay patients: Compounded evolocumab through a licensed Kentucky 503A pharmacy is the primary lower-cost option. Patients should also check GoodRx, RxSaver, and Cost Plus Drugs (Mark Cuban's pharmacy) for pricing on the branded product, though savings vary and these platforms do not consistently list evolocumab at prices far below list [20].

NeedyMeds and PAP programs: Amgen's Patient Assistance Program (PAP) provides free evolocumab to uninsured or underinsured patients who meet income eligibility criteria, typically at or below 400% of the federal poverty level. Applications are available through the Amgen Assist 360 program line.

Understanding Prior Authorization Requirements in Kentucky

Prior authorization (PA) is required by essentially every Kentucky payer that covers evolocumab. The PA process exists because PCSK9 inhibitors are high-cost specialty drugs, and payers want clinical documentation that a patient genuinely needs this level of LDL-C reduction. Typical PA criteria across Kentucky plans include:

A confirmed diagnosis of HeFH (by clinical criteria or genetic testing), HoFH, or established ASCVD. LDL-C above goal despite maximally tolerated statin therapy, defined as the highest dose the patient can tolerate before adverse effects. Documentation of ezetimibe use or a reason for ezetimibe intolerance. A prescribing physician's attestation that the clinical indication is appropriate [9].

The PA approval period is typically 12 months, after which reauthorization with updated lab values is required. Lipidologists and preventive cardiologists report higher first-pass approval rates than primary care providers because they can attach more complete clinical documentation [7].

If a PA is denied, the patient and prescriber have the right to a peer-to-peer review, during which the prescribing physician speaks directly with the plan's medical director. Peer-to-peer reviews for evolocumab often succeed when the prescriber can cite the FOURIER cardiovascular outcomes data and the ACC/AHA guideline recommendation, particularly for patients with established ASCVD and LDL-C persistently above 70 mg/dL [3].

Kentucky-Specific Programs and Discount Pathways

Beyond the Amgen savings card and PAP, Kentucky patients have several state-specific options worth exploring.

The Kentucky Health Benefit Exchange (Kynect) offers subsidized commercial plans for patients who lack employer coverage, and those commercial plans may include formulary coverage for evolocumab. Patients earning between 100% and 400% of the federal poverty level may qualify for premium subsidies that make a commercial plan cost-effective even for a single specialty drug [21].

Community health centers (Federally Qualified Health Centers, or FQHCs) operating under the 340B Drug Pricing Program can dispense 340B-discounted medications to eligible patients. Several Kentucky FQHCs participate in 340B, and evolocumab is 340B-eligible. Patients receiving care at an FQHC should ask the pharmacy staff whether evolocumab is available at the 340B price [22].

State pharmaceutical assistance programs vary; Kentucky does not operate a dedicated state pharmaceutical assistance program specifically for cholesterol drugs as of 2025. Patients should annually check the Kentucky Department for Medicaid Services and the SHIP (State Health Insurance Assistance Program) for updates.

Clinical Overview: Who Should Be on Evolocumab?

Evolocumab is indicated for adults who need LDL-C reduction beyond what statins and ezetimibe can achieve. The main patient groups are those with HeFH, HoFH, and established ASCVD (prior MI, stroke, or peripheral arterial disease) [2].

In FOURIER (N=27,564), patients on background statin therapy who received evolocumab 140 mg every 2 weeks achieved a mean LDL-C of 30 mg/dL, versus 92 mg/dL in the placebo group, a 59% reduction from baseline [3]. The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 11.3% of the evolocumab group versus 12.6% in placebo (HR 0.85, P<0.001) [3]. Secondary endpoint analysis showed a 20% reduction in the hard endpoint of cardiovascular death, MI, or stroke over the full follow-up period [3].

The GLAGOV trial (N=968) using intravascular ultrasound showed that evolocumab produced statistically significant regression of coronary atherosclerosis compared with placebo (mean percent atheroma volume change: evolocumab -0.95% vs. placebo +0.05%, P<0.001) [23]. That plaque regression finding, published in JAMA, provides biological confirmation that the LDL reductions translate into arterial benefit.

The 2022 ACC/AHA Cholesterol Guideline assigns a Class IIa recommendation (Level of Evidence: A) to adding a PCSK9 inhibitor in very-high-risk ASCVD patients with LDL-C greater than or equal to 70 mg/dL on maximally tolerated statin plus ezetimibe [7]. The guideline defines very-high-risk ASCVD as a history of multiple major ASCVD events or one major event plus multiple high-risk conditions.

Evolocumab is administered as a 140 mg subcutaneous injection every 2 weeks, or 420 mg once monthly using three consecutive 140 mg injections. Both regimens produce equivalent LDL-C reductions [2]. The monthly dosing option may improve adherence for patients who dislike the every-two-week schedule.

Common adverse effects include injection-site reactions (occurring in approximately 3.2% of patients in FOURIER), nasopharyngitis, and upper respiratory tract infection [3]. Serious adverse effects are rare; neurocognitive concerns raised in early post-marketing reports were not confirmed in the EBBINGHAUS cognitive substudy of FOURIER (N=1,974), which found no difference in cognitive function between evolocumab and placebo over 19 months [24].